Benefits of using empagliflozin in patients with type 2 diabetes mellitus and liver cirrhosis

• Leonid Yu. Morgunov
• Hafiz S. Mamedguseynov

Abstract

Due to the rapid increase of the prevalence of type 2 diabetes mellitus (T2DM) worldwide, the practically significant interest of the scientific community in the search for new glucose-lowering drugs is growing in parallel. The article demonstrates the results of a study that compares two classes of new oral hypoglycemic drugs - sodium glucose co-transporter type 2 inhibitors (iNGLT-2) (empagliflozin), and a selective reversible competitive inhibitor of dipetidyl peptidase-4 (saxagliptin) in patients with T2DM and liver cirrhosis. The study revealed the advantages of using iNGLT-2 agents in patients of this group.

Keywords:type 2 diabetes mellitus, liver cirrhosis, type 2 sodium-glucose cotransporter inhibitors, empagliflozin

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)